Sermo develops real-time medical mobile app for docs

Share this article:
Sermo develops real-time medical mobile app for docs
Sermo develops real-time medical mobile app for docs

Online physician community Sermo has launched a free medical app for its exclusive network of more than 120,000 physicians – called Sermo Mobile – which allows doctors to access medical information in real-time. The mobile app was built off of Sermo's current web platform, which provides an online resource to physicians nationwide, across 68 specialties, to consult and confer with on the highest quality care for their patients.

Sermo Mobile's iConsult feature is being touted as one of the biggest draws to the app, which allows a doctor to take a photograph of a physical ailment, x-ray or lab result, choose a question from the set list of applicable health queries, and send the message to relevant specialists in the Sermo network of physicians instantaneously. Other highlights of the app include easy access to the Sermo community's discussions about healthcare reform and clinical trials, the ability to author and track posts directly from a smart phone, and notifications that keep members flagged for new developments in medicine.

“Sermo Mobile allows members quick and eary access to the knowledge and expertise of leading PCPs and specialists throughout the country, anytime, anywhere,” says Sermo founder and CEO, Daniel Palestrant, MD, in a release. “Turning the concept of real-time medicine into reality has been our vision for some time, and this technology allows physicians to immediately impact patient care.”

The app is currently available on nationwide networks via the iPhone, iPad and iTouch. Sermo and partner Janssen Global Services, LLC, aim to continue working together to develop and deliver supplementary real-time services to help physicians provide the best point of care to their patients.
Share this article:

Email Newsletters

More in News

BMS Q2 sales slip, Eliquis, Yervoy soar

BMS Q2 sales slip, Eliquis, Yervoy soar

The company attributed part of the Eliquis boost to the BMS-Pfizer DTC and education efforts.

Gilead, Merck HCV marketing battle may be on horizon

Gilead, Merck HCV marketing battle may be on ...

Disclosed in its earnings report yesterday, Gilead may have a card up its sleeve to counter Merck's experimental hep. C combo regimen.

Sales of Biogen MS pill pick up overseas

Sales of Biogen MS pill pick up overseas

Biogen Idec is seeing strong sales for blockbuster MS drug Tecfidera, especially overseas where it's beginning to catch fire this summer.